Division of Urology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Urology. 2013 Apr;81(4):707-13. doi: 10.1016/j.urology.2013.01.009. Epub 2013 Feb 26.
To clearly define the proportions of benign vs malignant histologic findings in resected renal masses through an in-depth review of the contemporary medical data to assist in preoperative risk assessment.
PubMed and select oncology congresses were searched for publications that identify the histologic classification of resected renal masses in a representative sample from the contemporary data: [search] incidence AND (renal cell carcinoma AND benign); incidence AND (renal tumor AND benign); percentage AND (renal cell carcinoma AND benign); limit 2003-2011.
We identified 26 representative studies meeting the inclusion criteria and incorporating 27,272 patients. The frequency of benign tumors ranged from 7% to 33%, with most studies within a few percentage points of the mean (14.5% ± 5.2%, median 13.9%). Clear cell renal cell carcinoma occurred in 46% to 83% of patients, with a mean of 68.3% (median 61.3; SD = 11.9%). An inverse relationship between tumor size and benign pathologic features was identified in 14 of 19 (74%) studies that examined an association between tumor size and pathologic characteristics. A statistically significant correlation between clear cell renal cell carcinoma and tumor size was identified in 13 of 19 studies (63%). The accuracy of preoperative cross-sectional imaging was low in the 2 studies examining computed tomography (17%).
Benign renal tumors represent ∼15% of detected surgically resected renal masses and are more prevalent among small clinical T1a lesions. Noninvasive preoperative differentiation between more and less aggressive renal masses would be an important clinical advance that could allow clinicians greater diagnostic confidence and guide patient management through improved risk stratification.
通过深入回顾当代医学数据,明确界定切除的肾肿块的良性与恶性组织学发现的比例,以协助术前风险评估。
在 PubMed 和选定的肿瘤学年会上搜索发表的文献,这些文献在当代数据中代表样本确定切除的肾肿块的组织学分类:[搜索]发病率和(肾细胞癌和良性);发病率和(肾肿瘤和良性);(肾细胞癌和良性)的百分比;限制在 2003-2011 年。
我们确定了 26 项符合纳入标准的代表性研究,纳入了 27272 名患者。良性肿瘤的频率范围为 7%至 33%,大多数研究接近平均值(14.5%±5.2%,中位数 13.9%)。透明细胞肾细胞癌发生在 46%至 83%的患者中,平均为 68.3%(中位数 61.3;SD=11.9%)。在 19 项研究中有 14 项(74%)研究检查了肿瘤大小与病理特征之间的关系,发现肿瘤大小与良性病理特征之间存在反比关系。在 19 项研究中有 13 项(63%)研究发现透明细胞肾细胞癌与肿瘤大小之间存在统计学显著相关性。在检查计算机断层扫描的 2 项研究中,术前横断面成像的准确性较低(17%)。
良性肾肿瘤占检测到的手术切除的肾肿块的约 15%,在较小的临床 T1a 病变中更为常见。术前非侵入性区分更具侵袭性和侵袭性较小的肾肿块将是一项重要的临床进展,可使临床医生更有诊断信心,并通过改善风险分层指导患者管理。